New drug tested to keep aggressive blood cancers at bay after transplant
NCT ID NCT05991973
Summary
This study tested whether adding a low-dose drug called chidamide after a stem cell transplant could help prevent cancer from returning in patients with T-cell leukemia or lymphoma. It involved 44 patients who had already received a transplant and were in remission but at high risk of relapse. Researchers monitored patients for two years to see if the maintenance therapy improved survival and prevented relapse without causing severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, 310006, China
Conditions
Explore the condition pages connected to this study.